{
  "nctId": "NCT04068051",
  "briefTitle": "Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)",
  "officialTitle": "An Open-Label, Long-Term Study to Assess the Safety and Efficacy of AXS-07 (MoSEICâ„¢ Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults",
  "protocolDocument": {
    "nctId": "NCT04068051",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2019-10-17",
    "uploadDate": "2023-09-15T17:33",
    "size": 535971,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04068051/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 706,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2019-07-06",
    "completionDate": "2020-09-22",
    "primaryCompletionDate": "2020-09-22",
    "firstSubmitDate": "2019-07-27",
    "firstPostDate": "2019-08-28"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Has participated in a prior study with AXS-07 for the treatment of migraine\n\nExclusion Criteria:\n\n* Has previously received any investigational drug or device or investigational therapy within 30 days before Screening, other than AXS-07\n* Pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "65 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Long-term Safety of Chronic Intermittent Use of AXS-07",
        "description": "Long-term safety as measured by:\n\nSubjects with any TEAEs\n\nSubjects with suspected to be drug-related TEAEs\n\nSubjects with serious TEAEs\n\nSubjects with TEAEs that led to drug withdrawal\n\nSubjects with TEAEs that led to withdrawal from study\n\nSubjects with TEAEs that resulted in death",
        "timeFrame": "Up to 12 months"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 1
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 14,
    "complexityCategory": "Simple"
  },
  "collectionDate": "2025-09-22T02:29:53.524Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}